glp-1-directed nmda receptor antagonism for obesity treatment GLP-1 Agonists In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Glucagon-Like Peptide-1: New Regulator in
Description
To view or add a comment, sign in More Relevant Posts GLP-1 medications are gaining attention for their impact on weight management and chronic conditions, but employers must carefully evaluate the cost and long term value of coverage
As an adaptation to leptin resistance, intestinal L-cells released GLP-1 in response to increased postprandial energy levels
Novel Dual Glp-1/Gip receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
J Neurosci Res (2003) 72(5):60312
Postprandial levels of GIP have been reported to be similar 2 weeks after (22) or higher 1 month (25) after RYGB compared to preoperative levels
